We are live on ! Find out more
LSB

LakeShore Biopharma
LSB

Delisted

LSB was delisted on the 19th of September, 2025.

Back to rankings

12 hedge funds and large institutions have $8.93M invested in LakeShore Biopharma in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

0% more ownership

Funds ownership: 1.2% → 1.2% (+0%)

25% less funds holding

Funds holding: 16 → 12 (-4)

42% less capital invested

Capital invested by funds: $15.4M → $8.93M (-$6.44M)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

Holders
12
Holders Change
-4
Holders Change %
-25%
% of All Funds
0.19%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
2
Increased
1
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$280K
2
CAC
Cowen and Company
New York
+$14.3K
3
TRCT
Tower Research Capital (TRC)
New York
+$254

Top Sellers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
-$119K
2
PCM
Prelude Capital Management
New York
-$44.4K
3
FSI
Flow State Investments
Illinois
-$40.9K
4
XT
XTX Topco
Cayman Islands
-$31.1K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$21.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$3.63M +$280K +24,295 +6%
Fidelity International
2
Fidelity International
Bermuda
$2.16M -$14.8K -1,283 -0.5%
VAM
3
Valliance Asset Management
Hong Kong
$1.29M – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$932K – – –
HA
5
HHLR Advisors
Cayman Islands
$601K – – –
SLM
6
Snow Lake Management
California
$286K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$10.9K – – –
CAC
8
Cowen and Company
New York
$9.88K +$14.3K +1,236 New
Barclays
9
Barclays
United Kingdom
$4.55K -$119K -10,320 -95%
PAM
10
Pinpoint Asset Management
Hong Kong
$2.06K – – –
WAM
11
Wolverine Asset Management
Illinois
$399 – – –
TRCT
12
Tower Research Capital (TRC)
New York
$177 +$254 +22 New
PCM
13
Prelude Capital Management
New York
– -$44.4K -3,220 Closed
FSI
14
Flow State Investments
Illinois
– -$40.9K -2,966 Closed
XT
15
XTX Topco
Cayman Islands
– -$31.1K -2,251 Closed
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
– -$21.1K -1,526 Closed
HF
17
HRT Financial
New York
– -$14K -1,050 Closed
UBS Group
18
UBS Group
Switzerland
– -$9.73K -705 Closed

LSB Hedge Fund Activity: Q3 2023 in Review

12 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma (LSB) for Q3 2023, worth a combined $8.93M — down 42% from $15.4M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of LSB and 2 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was OrbiMed, adding an estimated $280K. The largest seller was Barclays, cutting an estimated $119K.

  • 12 institutional investors held LakeShore Biopharma (LSB) as of Q3 2023, down from 16 in Q2 2023.
  • Funds reported $8.93M of LakeShore Biopharma stock for Q3 2023, down 42% quarter-over-quarter.
  • 2 funds opened new LakeShore Biopharma positions in Q3 2023 and 6 closed out, a net change of -4 holders.
  • The largest LakeShore Biopharma buyer in Q3 2023 was OrbiMed, an estimated $280K added.
  • The largest LakeShore Biopharma seller in Q3 2023 was Barclays, an estimated $119K sold.

Based on aggregated 13F filings for Q3 2023.